FDA Clears Vintage Ear Drops for Continued Sale
Published Date: 5/9/2025
Notice
Summary
The FDA checked and confirmed that certain drugs, like VOSOL 2% Otic Solution, weren’t taken off the market because they’re unsafe or don’t work. This means these drugs can keep being sold, and new versions can still get approved if they follow the rules. If you’re a drug maker or user, no sudden changes or costs are coming your way right now!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Listed Drugs Remain Approved
You can keep buying the listed drug products because the FDA found they were not withdrawn from sale for reasons of safety or effectiveness. The FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these products, so the products can continue to be sold.
Generics Can Still Be Approved
If you make generic drugs, the FDA will continue approving abbreviated new drug applications (ANDAs) that refer to these listed products as long as the applications meet legal and regulatory requirements. The FDA also will not begin procedures to withdraw approvals of ANDAs that refer to these products.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Previous / Next Documents
Previous: 2025-08206 — Office of the Comptroller of the Currency Agency Information Collection Activities: Information Collection Renewal; Comment Request; Consumer Protections for Depository Institution Sales of Insurance
The OCC is renewing its info collection about how banks sell insurance to protect consumers. Banks and insurance sellers will keep sharing info, but the OCC wants your thoughts to keep paperwork light and clear. This update helps make sure rules stay fair without extra hassle, with no new costs or deadlines yet.
Next: 2025-08208 — Prescription Drug User Fee Act VII; Independent Assessment of Communication Through Product Quality Information Requests During Application Review; Final Report; Availability; Request for Comments
The FDA just released a report checking how well they and drug makers talk during the review of new medicine applications. This is part of a promise under the Prescription Drug User Fee Act to make communication clearer and faster. Drug companies and the public can now see the report and share their thoughts to help improve the process by 2027.